Intercellular adhesion molecule, plasma adiponectin and albuminuria in type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 95, Issue 1, 2012, Pages 55-61

  Lenghel, Alina Ramona ^a   Kacso, Ina Maria ^a   Bondor, Cosmina Ioana ^a   Rusu, Crina ^a   Rahaian, Rodica ^b   Gherman Caprioara, Mirela ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b EMERGENCY COUNTY HOSPITAL   (Romania)

Author keywords

Adiponectin; Albuminuria; ICAM 1; Inflammation; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ALBUMIN URINE LEVEL; ALBUMINURIA; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINE LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ALBUMINURIA; CHEMOKINE CCL2; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 84355162997     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.08.028     Document Type: Article

References (46)

1. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
2. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes mellitus: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86(5):1930-1935.
3. Chow F., Ozols E., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004, 65:116-128.
4. Chow F.Y., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004, 19:2987-2996.
5. Nguyen D., Ping F., Mu W., Hill P., Atkins R.C., Chadban S.J. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006, 11:226-231.
6. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7(9):678-689.
7. Okada S., Shikata K., Matsuda M., Ogawa D., Usui H., Kido Y., et al. Intercellular adhesion molecule-1 deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52(10):2586-2593.
8. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Tesch G.H. Intracellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005, 16:1711-1722.
9. Rollins B.J. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996, 2:198-204.
10. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000, 58(2):684-690.
11. Morii T., Fujita H., Narita T., Shimotomai T., Fujishima H., Yoshioka N., et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 2003, 17(1):11-15.
12. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008, 294(4):697-701.
13. Kiyici S., Erturk E., Budak F., Ersoy C., Tuncel E., Duran C., et al. Serum monocyte chemoattractant Protein-1 and monocyte adhesion molecules in Type 1 diabetic patients with nephropathy. Arch Med Res 2006, 37:998-1003.
14. Navarro-González J.F., Mora-Fernández C., Muros de Fuentes M., García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011, 7(6):327-340.
15. Zhu W., Cheng K.K., Vanhoutte P.M., Lam K.S., Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci 2008, 114:361-374.
16. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005, 97:1245-1252.
17. Wiecek A., Adamczak M., Chudek J. Adiponectin-an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007, 22:981-988.
18. Levey A.S., Greene T., Kusek J.W., Beck G.J. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000, 11:828-830.
19. Tesch G.H., Lim A.K. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2011, 300(2):301-310.
20. Coimbra T.M., Janssen U., Gröne H.J., Ostendorf T., Kunter U., Schmidt H., et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000, 57:167-182.
21. Matsui H., Suzuki M., Tsukuda R., Iida K., Miyasaka M., Ikeda H. Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty. Diabetes Res Clin Pract 1996, 32:1-9.
22. Lin J., Glynn R.J., Rifai N., Manson J.E., Ridker P.M., Nathan D.M., et al. Inflammation and progressive nephropathy in Type 1 diabetes in the diabetes control and complications trial. Diabetes Care 2008, 31(12):2338-2343.
23. Ma J., Möllsten A., Prázny M., Falhammar H., Brismar K., Dahlquist G., et al. Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy. Diabet Med 2006, 23(10):1093-1099.
24. Astrup A.S., Tarnow L., Pietraszek L., Schalkwijk C.G., Stehouwer C.D., Parving H.H., et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008, 31(6):1170-1176.
25. Upadhyay A., Larson M.G., Guo C.Y., Vasan R.S., Lipinska I., O'Donnell C.J., et al. Inflammation: kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011, 26(3):920-926.
26. Guler S., Cakir B., Demirbas B., Yönem A., Odabasi E., Onde U., et al. Plasma soluble intercellular adhesion molecules 1 levels are increased in type 2 diabetic patients with nephropathy. Horm Res 2002, 58:67-70.
27. Bruno C.M., Valenti M., Bertino G., Ardiri A., Bruno F., Cunsolo M., et al. Plasma ICAM-1 and VCAM-1 levels in type 2 diabetic patients with and without microalbuminuria. Minerva Med 2008, 99(1):1-5.
28. Persson F., Rossing P., Hovind P., Stehouwer C.D., Schalkwijk C.G., Tarnow L., et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Scand J Clin Lab Invest 2008, 68(8):731-738.
29. Rubio-Guerra A.F., Vargas-Robles H., Lozano Nuevo J.J., Escalante-Acosta B.A. Correlation between circulating adhesion molecule levels and albuminuria in type-2 diabetic hypertensive patients. Kidney Blood Press Res 2009, 32(2):106-109.
30. Rubio-Guerra A.F., Vargas-Robles H., Ayala G.V., Escalante-Acosta B.A. Correlation between circulating adhesion molecule levels and albuminuria in type 2 diabetic normotensive patients. Med Sci Monit 2007, 13(8):CR349-CR352.
31. Kamel L., Morsy A., El Shamaa A. T-cell cytokine production and endothelial dysfunction in type 2 diabetic patients with nephropathy. East Mediterr Health J 2009, 15(4):807-816.
32. Salmenniemi U., Ruotsalainen E., Pihlajamaki J., Vauhkonen I., Kainulainen S., Punnonen K., et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004, 110(25):3842-3848.
33. Manju Chandran S.A.P., Ciaraldi T., Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003, 26(8):2442-2450.
34. Yenicesu M., Yilmaz M.I., Caglar K., Sonmez A., Eyileten T., Kir T., et al. Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients. Clin Nephrol 2005, 64:12-19.
35. Von Eynatten M., Hamann A., Twardella D., Nawroth P.P., Brenner H., Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006, 52(5):853-859.
36. Ramos L.F., Shintani A., Himmelfarb J., Ikizler T.A. Determinants of plasma adiponectin levels in nondiabetic subjects with moderate to severe chronic kidney disease. J Ren Nutr 2009, 19(3):197-203.
37. Stefan N., Stumvoll M., Vozarova B., Weyer C., Funahashi T., Matsuzawa Y., et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003, 26(12):3315-3319.
38. Looker H.C., Krakoff J., Funahashi T., Matsuzawa Y., Tanaka S., Nelson R.G., et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004, 89(8):4010-4017.
39. Barlovic D.P., Zaletel J., Prezelj J. Adipocytokines are associated with renal function in patients with normal range glomerular filtration rate and type 2 diabetes. Cytokine 2009, 46(1):142-145.
40. Komaba H., Igaki N., Goto S., Yokota K., Doi H., Takemoto T., et al. Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 2006, 26(5):476-482.
41. Kato K., Osawa H., Ochi M., Kusunoki Y., Ebisui O., Ohno K., et al. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin Endocrinol (Oxf) 2008, 68:442-449.
42. Ohashi K., Iwatani H., Kihara S., Nakagawa Y., Komura N., Fujita K., et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007, 27(9):1910-1917.
43. Sharma K., Ramachandrarao S., Qiu G., Usui H.K., Zhu Y., Dunn S.R., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008, 118(5):1645-1656.
44. Zoccali C., Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum?. Kidney Int 2007, 71(12):1195-1197.
45. Zoccali C., Mallamaci F. Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers?. J Ren Nutr 2011, 21(1):87-91.
46. Ouedraogo R., Gong Y., Berzins B., Wu X., Mahadev K., Hough K., et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007, 117(6):1718-1726.